BioCentury
ARTICLE | Clinical News

Bosulif bosutinib: Completed Phase III enrollment

September 21, 2015 7:00 AM UTC

Avillion completed enrollment of 536 patients in the open-label, international Phase III BFORE trial comparing 400 mg oral Bosulif once daily vs. 400 mg oral Gleevec imatinib once daily for 5 years. ...